Sign in
WithdrawnNo phase

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Key facts

Who runs it
Fudan University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Jan 2020
Ended
31 May 2024
Type of study
Observational
Treatments tested
  • Fruquintinib Combined With TAS-102
Record updated
3 August 2026
Why it stopped
The study was withdrawn before participant enrollment because the research team decided not to initiate the study after reassessing its feasibility.

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Histology-confirmed metastatic CRC (mCRC)
  • Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
  • Fruquintinib administered as salvage treatment
  • Age: 18-75 years old
  • Informed consent

Who cannot take part

  • Drug administration stopped after less than two cycles
  • Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
  • Fruquintinib and/or TAS-102 administration as second-line treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.

The group in the trial

  • Fru plus TAS-102

    mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line

    Treatment: Fruquintinib Combined With TAS-102

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single-center, Prospective Cohort Study of Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Record updated
3 August 2026